Schizophrenia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are able to give informed consent to take part in the study
- People who can understand and speak a Scandinavian language
- People who have been diagnosed with a schizophrenia spectrum disorder (such as schizophrenia, schizoaffective disorder, or schizophreniform disorder) according to standard international diagnostic guidelines
Who may not be able to join:
- People who have a diagnosis of intellectual disability
- People who have a diagnosed neurological disorder (a condition affecting the brain or nervous system)
- People who have a history of severe head trauma
- People who are pregnant
- People who experience chest pain during physical activity
- People who have unstable angina pectoris (a serious type of chest pain caused by reduced blood flow to the heart)
- People who have malignant hypertension (dangerously high blood pressure)
- People who have an uncontrollable irregular heartbeat
- People who have recently had a heart attack
- People who have an active infection accompanied by swollen lymph nodes (glands)
- People who have another medical condition that the trial site determines is not compatible with participation (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Tom Langerud Holmen, PhD, Sykehuset i Vestfold HF
Phone: 97119323
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Improved cognition as measured by increased scores on the MCCB test battery.; Sustained motivation for the intervention activity (exergaming) as measured by high attendance/adherence to protocol and low levels of drop-out/withdrawal, respectively.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.